In a groundbreaking study on 171 NMOSD patients, researchers found that a decrease in Aquaporin-4 antibody titers led to a significant reduction in relapse rates. Specifically, 25.7% of patients became AQP4-IgG seronegative, resulting in a remarkable decrease in annualized relapse rate. The decline in AQP4-IgG levels was identified as a protective factor against relapse, highlighting […]
Category: monoclonal antibodies
Monoclonal Antibodies for Rheumatoid Arthritis Treatment
Recent advancements in the treatment of rheumatoid arthritis (RA) have been revolutionized by the introduction of monoclonal antibodies (mAbs). These biologics target specific cytokines and cellular components in the RA synovium, offering a promising approach to achieving remission in clinical, functional, and radiographic aspects of the disease. Early studies focused on mAbs targeting CD4, CD7, […]
